Sharing Clinical Findings from Modulating Myeloid Cells at Their Inception with Small Activating RNA Therapies to Enhance Anti-Tumor Activity

Time: 11:30 am
day: Day Two


• Describing the mode of action of saRNA therapies targeting naïve myeloid cells

• Developing a preclinical package for next-generation myeloid-targeted therapies and translating them into the clinic

• Outlining how indications and patient populations were chosen, and how to best utilize tumor biomarkers as an indicator mechanism

• Sharing patient outcomes, toxicology studies, and dose escalation rationale